Lundbeck, Kyowa Hakko Kirin deal

Kyowa granted H. Lundbeck exclusive rights to develop and commercialize KW-6356 outside Asia and Japan. The adenosine A2A receptor (ADORA2A) antagonist is in preclinical testing to treat Parkinson's disease (PD), with Phase I testing expected to start next year. Lundbeck also has the right to select back-up or additional compounds. ...